北京若生智能科技有限公司
Drug Database
CA

calcitonin (Fortical Injection / Forcaltonin)

✓ Approved

Kyowa Kirin Co., Ltd. · CALCR · 重组蛋白

什么是 calcitonin？

calcitonin 是一种重组蛋白，由Kyowa Kirin Co., Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Fortical Injection, Forcaltonin
公司Kyowa Kirin Co., Ltd.
药物类别重组蛋白
分子靶点CALCR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Kyowa Kirin Co., Ltd.

作用机制

分子靶点

calcitonin 作用于 1 个分子靶点：

CALCRcalcitonin receptor (CT-R, CTR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

calcitonin 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersHypercalcaemia of malignancy✓ Approved
Musculoskeletal and connective tissue disordersOsteitis deformans✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedClinical chemistry and laboratory medicine2026-09-10

Pre-analytical and analytical validation of calcitonin measurement in fine needle aspiration cytology washout.

Mater Amber A, Heijboer Annemieke C AC, Boelen Anita A, de Graaf Pim P et al.

Current guidelines advise calcitonin measurements in washout from fine needle aspiration cytology (FNAC) upon inconclusive cytological examination of medullary thyroid cancer (MTC). (Pre-)analytical validation studies of calcitonin measurements in FNAC washout are however missing. In this study, we examined (pre-)analytical aspects of calcitonin measurements using three washout solvents, aiming to provide insights for implementation of calcitonin measurements in FNAC washout as a supplementary test for diagnosing and monitoring patients with MTC. Validation studies were performed using CytoLyt, NaCl and MultiDiluent as washout solvents. Precision (intra- and inter-assay coefficients of variation (CV)), accuracy (linearity and recovery) and storage stability of each solvent were assessed after spiking with calcitonin standard. Calcitonin measurements were performed using the serum CALCT immunoassay (Siemens, Atellica). Decision criteria were set based on CLSI and manufacturer's manual. Measurements of calcitonin in MultiDiluent met all decision criteria: intra- and inter-assay CVs were ≤5.5 % and ≤9 %, serial dilutions were linear (R2=0.997) and median recovery was 148 % with limited variation. Furthermore, calcitonin concentrations remained stable (<10 % change) after storage. Measurements in CytoLyt were precise and accurate, but unstable upon storage. Measurements in NaCl only met the criteria for intra-assay CV and linearity. This study showed that MultiDiluent was the optimal solvent to use for calcitonin measurements in a non-serum matrix using the Atellica calcitonin immunoassay. CytoLyt performed suboptimal, while the performance of NaCl was poor. Further research is needed to validate the recommended work-up using patient-derived material.

PMID 42720008
阅读全文 →
PubMedInnovation (Cambridge (Mass.))2026-09-10

Erratum: Sodium-ion-responsive injectable supramolecular hydrogel delivers engineered Salmonella for safer and enhanced tumor immunotherapy.

Yu Wenliang W, Tang Wei W, Zhang Tao T, Gao Mengyue M et al.

[This corrects the article DOI: 10.1016/j.xinn.2026.101363.].

PMID 42719758
阅读全文 →
PubMedThe AAPS journal2026-09-10

In Vitro Release Testing for Long Acting Injectables - a Workshop Summary Report.

Flanagan Talia T, Burgess Diane D, Duvnjak Marieta M, Fotaki Nikoletta N et al.

A three-session webinar series was held by the IQ Consortium in early May 2023 on the topic of in vitro release testing of long acting injectable and parenteral (non-oral) drug products. Attendance was excellent, indicating the high level of interest in this topic. This paper provides a high-level overview of the talks that were given during the webinar and the open discussion session.

PMID 42717135
阅读全文 →
PubMedInnovation (Cambridge (Mass.))2026-09-10

Sodium-ion-responsive injectable supramolecular hydrogel delivers engineered Salmonella for safer and enhanced tumor immunotherapy.

Yu Wenliang W, Tang Wei W, Zhang Tao T, Gao Mengyue M et al.

Live bacterial therapeutics (LBTs) based on attenuated Salmonella Typhimurium VNP20009 (VNP) show great promise for refractory cancer treatment. However, improvements in antitumor efficacy are often accompanied by increased systemic toxicity. To address this critical challenge of achieving both potent efficacy and acceptable safety, this study developed a sodium-ion-responsive, injectable supramolecular hydrogel suitable for VNP delivery, isosteviol-1,6-diester sodium sulfonate (1,6-DAS). By encapsulating engineered VNP (VNP-TNF-α nanobody [nb]) within this hydrogel for intraperitoneal delivery in murine melanoma models, not only was 78.8% of bacteria-induced body weight loss alleviated and VNP-associated hepatosplenomegaly, necrosis, tissue damage, and immune dysregulation completely prevented, but antitumor immune responses were also further enhanced. The findings indicate that the 1,6-DAS hydrogel achieves comprehensive attenuation of VNP through a dual mechanism whereby slow release lowers acute bacterial burden in the liver and spleen and binding of 1,6-DAS molecules to VNP flagellin attenuates its immunogenicity. In addition, delivery of the VNP-TNF-α nb via the 1,6-DAS hydrogel further enhances antitumor immunity by upregulating and activating dendritic cells (DCs) and CD8+ T cells in the tumor microenvironment. Overall, the 1,6-DAS hydrogel provides a promising approach to address the core challenge of balancing efficacy and safety in VNP-based therapies, with substantial potential to propel microbiome-driven cancer immunotherapy forward.

PMID 42719311
阅读全文 →
PubMedFrontiers in psychiatry2026-09-10

Low willingness and patient-caregiver concordance regarding long-acting injectable antipsychotics in schizophrenia cases: a convergent mixed-methods study.

Zhang Huaiming H, Wu Bo B, Zhou Jin J, Bai Pengnan P et al.

Long-acting injectable antipsychotics (LAIAs) may improve treatment continuity in schizophrenia, yet their acceptance in community-based care remains limited. This study examined factors associated with willingness to use LAIAs and dyadic perceptions and barriers among patients with schizophrenia and their primary caregivers in Yangpu District, Shanghai, where LAIA services and financial support were available. This convergent mixed-methods study included a paired questionnaire survey of 425 community-managed patients who met LAIA treatment criteria but had not used LAIAs and their primary caregivers. Semi-structured interviews were conducted with 32 patient-caregiver dyads until information saturation was reached. Quantitative and qualitative findings were integrated using a joint display. Willingness to use LAIAs was low among patients and caregivers (17.4% and 17.6%), and awareness was limited in both groups (26.6% and 28.0%). Four dyadic willingness profiles were identified: concordant unwillingness, patient-only willingness, caregiver-only willingness, and concordant willingness. Higher patient willingness was associated with female sex, patient LAIA awareness, physician recommendation at the highest frequency, and caregiver willingness, whereas higher caregiver willingness was associated with caregiver LAIA awareness, being married, and patient willingness. Qualitative findings explained low acceptance through safety and injection concerns, treatment inertia, limited knowledge, reliance on physicians, family-based decision-making, and service accessibility barriers. These findings suggest that supporting informed LAIA acceptance may require patient-caregiver-centered decision support, safety communication, and coordinated follow-up beyond service availability and cost support.

PMID 42718872
阅读全文 →
PubMedAdvances in therapy2026-09-10

Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.

Sawaya M Farris MF, McNulty Molly E ME, Germain Collin J St CJS, Hachem Ibraheem A IA et al.

Substance use disorders are an increasing concern globally, causing a tremendous uptick in public health burden in recent years. Despite the growing attention these disorders receive, there remain no approved pharmacotherapies for stimulant use disorder, thereby contributing a major portion of this burden. This review examines the potential use of Brixadi, an extended-release injectable formulation of the widely used pharmacotherapy buprenorphine, indicated for opioid use disorder, in the treatment of stimulant use disorder. Psychostimulants, including cocaine, methamphetamine, and designer stimulants, all exert their effects by inhibiting or reversing the directionality of the monoamine transporters in the synaptic cleft. Inhibition or reversal of these transporters in the synaptic cleft allows dopamine, serotonin, and norepinephrine to remain in the synapse, which ultimately enhances their activity and contributes to the reinforcement of substance use. The reinforcement loop driven by excess neurotransmitters, particularly dopamine, provides a pharmacotherapeutic target via receptor interactions. Brixadi is an injectable extended-release buprenorphine primarily used to treat opioid use disorder. The extended-release mechanism enables sustained drug-receptor interaction, resulting in stable plasma drug concentrations. Buprenorphine is as a dual-acting agent, a partial μ-opioid receptor (MOR) agonist and a κ-opioid receptor (KOR) antagonist. KOR antagonism modulates symptoms of withdrawal in OUD, including dysphoria, stress, and drug cravings. Therefore, Brixadi's KOR antagonism may offer a promising pharmacologic target for stimulant use disorder recovery by mitigating these negative affective states. Additionally, the bimodal mechanism suggests that Brixadi may be a beneficial pharmacologic candidate for people who suffer from polysubstance use involving opioids and psychostimulants. While there is promise behind these developments, current studies are limited to preclinical trials and have not yet advanced toward clinical trials. However, Brixadi's extended-release profile and potential capability to minimize withdrawal-related dysphoria and stress-induced drug seeking present promise for further clinical investigation.

PMID 42720725
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多calcitonin